Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - sykursýki, tegund 2 - lyf notuð við sykursýki - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 fyrir tiltæk gögn um mismunandi samsetningar).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - lyf notuð við sykursýki - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

laboratoire hra pharma - ulipristal - getnaðarvörn, postcoital - hormón kynlíf og stillum á kynfærum kerfi, , neyðarástand getnaðarvarna - neyðartilvikum getnaðarvörn innan 120 klukkustundir (fimm daga) varnarlausa samfarir eða getnaðarvörn bilun.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimus monohydrate; tacrolimus - hart forðahylki - 5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atorvastatin kalsíum tríhýdrat - filmuhúðuð tafla - 10 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50mg/1000 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - metforminum hýdróklóríð; sitagliptinum hýdróklóríð - filmuhúðuð tafla - 50/1000 mg